Since GLP-1 drugs were approved for obesity in 2021, prescriptions among adults rose from 0.5% to just over 2% by 2024, according to FAIR Health data analyzed by the USDA Office of the Chief Economist
More promising results, however, were announced the same month by Eli Lilly for its new once-daily GLP-1 pill which showed promise for weight management and for the treatment of type-2 diabetes
We believe that hypoglycemia post-bariatric surgery is potentially more common than reported
Contracting favors platforms that document outcomes and control medication-related spend
Sohum S, AP, MF, MM, AR, RS, Siddharth S, and BLW: Writingreview & editing
36 Collectively, these data support a growing body of evidence of the promising role of GLP-1RAs in retinal health